Rexahn, KRICT Form Licensing Partnership

Rexahn Pharmaceuticals has entered into a licensing partnership with Korea Research Institute of Chemical Technology (KRICT). The deal is regarding the development of a synthetic process for Quinoxalines compounds.

Chang Ahn, Chairman and CEO of Rexahn, said: “Partnership with KRICT will further enrich our growing pre-clinical drug pipeline devoted to new therapies that change treatment paradigms in cancer and CNS. The Quinoxaline family of compounds is very promising, and we expect to bring Quinoxaline-based drugs into the clinical trial process and ultimately to market.”

Under the terms of the agreement, Rexahn would acquire all intellectual properties related to Quinoxaline-Piperazine derivatives (that were synthesized under a previous Joint Research Agreement) by exercising its option to receive an exclusive license to use, develop and commercially exploit the intellectual properties.